Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Allergic Rhinitis AND Asthma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    206 result(s) found for: Allergic Rhinitis AND Asthma. Displaying page 6 of 11.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    EudraCT Number: 2018-002596-18 Sponsor Protocol Number: Lais-Birch-Alder-18-19 Start Date*: 2018-10-12
    Sponsor Name:LOFARMA S.P.A.
    Full Title: Efficacy and Safety of sublingual immunotherapy with Allergoid LAIS Birch tablets for patients with tree pollen-induced allergic rhinoconjunctivitis with or without mild controlled asthma
    Medical condition: Tree pollen-induced allergic rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    20.0 100000004870 10036019 Pollen allergy LLT
    20.1 100000004870 10066093 Birch pollen allergy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-001914-41 Sponsor Protocol Number: AL1201AV Start Date*: 2012-10-19
    Sponsor Name:Allergopharma Joachim Ganzer KG
    Full Title: Open label phase II multicentre clinical trial to evaluate safety during shortened uptitration of an allergoid grass pollen preparation in adult patients with IgE mediated allergic rhinitis / rhino...
    Medical condition: ICD classificationcode: J 45.0 and J30.1 Patients with IgE mediated allergic rhinitis / rhinoconjunctivitis with or without controlled bronchial asthma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10001728 Allergic rhinoconjunctivitis LLT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-004669-15 Sponsor Protocol Number: CP007A Start Date*: 2014-06-16
    Sponsor Name:Circassia Limited
    Full Title: An Optional Prospective Follow-on Study to Evaluate the Continued Efficacy and Safety of Cat-PAD in Cat Allergic Subjects up to Five Years after the Administration of Treatment
    Medical condition: Treatment of cat allergen induced rhinoconjunctivitis in patients with clinically relevant symptoms
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004855 10034382 Perennial allergic rhinitis LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed) DE (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-003008-12 Sponsor Protocol Number: ALU 04.05 E Start Date*: 2005-11-04
    Sponsor Name:STALLERGENES
    Full Title: Prospective trial to evaluate the safety of one cluster regimen in patients with allergic rhinitis/ rhinoconjunctivitis and/or mild or moderate allergic asthma to grass polen, tree pollen or mites....
    Medical condition: Allergic rhinitis / rhinoconjunctivitis and/or mild or moderate allergic asthma to grass pollen, tree pollen or mites.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-002477-22 Sponsor Protocol Number: R1908-1909-ALG-1703 Start Date*: 2019-01-25
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY IN CAT-ALLERGIC PATIENTS WITH ASTHMA TO EVALUATE THE EFFICACY OF A SINGLE DOSE OF REGN1908-1909 TO REDUCE BRONCHOCONSTR...
    Medical condition: Cat-allergic asthma and Bronchoconstriction Upon Cat Allergen Challenge
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10001705 Allergic asthma LLT
    20.0 100000004855 10006464 Bronchoconstriction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-018621-19 Sponsor Protocol Number: MT-04 Start Date*: 2011-09-30
    Sponsor Name:ALK-Abelló A/S
    Full Title: Efficacy of ALK house dust mite allergy immunotherapy tablet in subjects with house dust mite induced asthma. The MITRA Trial.
    Medical condition: House dust mite induced allergic asthma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001705 Allergic asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) SK (Completed) LT (Completed) ES (Completed) GB (Completed) AT (Completed) NL (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2015-002105-11 Sponsor Protocol Number: BTT-gpASIT009 Start Date*: 2015-11-10
    Sponsor Name:BioTech Tools S.A.
    Full Title: A multicenter, international, randomised, double-blind, placebo controlled study to demonstrate the clinical efficacy and safety of a subcutaneous immunotherapy with gpASIT+™ in patients with grass...
    Medical condition: Treatment of seasonal grass pollen rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004870 10019170 Hay fever LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) CZ (Completed) ES (Completed) FR (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-005269-20 Sponsor Protocol Number: 6078-PG-PSC-158 Start Date*: 2007-01-15
    Sponsor Name:LETI Pharma GmbH
    Full Title: Randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy of Depigoid® Grass Mix as a rush immunotherapy in patients with allergic rhinitis using an environmental ...
    Medical condition: Allergic rhinitis and/or rhinoconjunctivitis with or without mild intermittent asthma caused by clinical relevant sensitization against grass pollen.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039083 Rhinitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-003860-47 Sponsor Protocol Number: CIGE025ADE03 Start Date*: 2006-02-20
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A randomized, 20 week, double-blind, placebo-controlled, parallel-group, multiple-dose, multicenter study to assess the efficacy and safety of Omalizumab in combination with Depigoid, versus Depigo...
    Medical condition: Asthma extrinsic
    Disease: Version SOC Term Classification Code Term Level
    M15 10003558 LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-005911-82 Sponsor Protocol Number: AL0506st Start Date*: 2007-04-02
    Sponsor Name:Allergopharma GmbH & Co. KG
    Full Title: A multicenter, placebo-controlled, double-blind study to evaluate efficacy and safety of a perennial sublingual specific immunotherapy with a solution of grass pollen allergen extract in children w...
    Medical condition: IgE-mediated allergic disease manifested as symptoms of allergic rhinitis/rhinoconjunctivitis with or without allergic bronchial asthma (GINA I und II) triggered by grass pollen allergens.
    Disease: Version SOC Term Classification Code Term Level
    18.1 10021428 - Immune system disorders 10048908 Seasonal allergy PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2006-003216-22 Sponsor Protocol Number: 793 Start Date*: 2006-06-15
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: Effects of montelukast on airway inflammation in allergic children
    Medical condition: airway inflammation asthma in allergic children
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003553 Asthma LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-006261-81 Sponsor Protocol Number: PM/0028 Start Date*: 2009-06-24
    Sponsor Name:HAL Allergy
    Full Title: Dose Tolerability Study with High Dose PURETHAL Mites in Allergic Rhinitis / Rhinoconjunctivitis Patients. An open study to assess tolerability, safety and short-term efficacy of high dose PURETHA...
    Medical condition: Allergic (IgE-mediated) rhinitis / rhinoconjunctivitis triggered by house dust mites.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001725 Allergic rhinitis due to other allergen LLT
    9.1 10053713 Allergenic desensitisation procedure LLT
    9.1 10053741 Allergenic desensitization procedure LLT
    9.1 10001709 Allergic conjunctivitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-003892-35 Sponsor Protocol Number: AL 0104 av Start Date*: 2005-04-01
    Sponsor Name:ALLERGOPHARMA JOACHIM GANZER KG
    Full Title: A multicentre randomised placebo-controlled double-blind clinical trial for evaluation of safety and efficacy of specific immunotherapy with an aluminium hydroxide-adsorbed Allergoid Preparation of...
    Medical condition: IgE-mediated allergic disease in adults and children manifested as bronchial asthma (GINA II and III) +/-allergic rhinitis/rhinoconjunctivitis, triggered by non-eliminable house dust mite allergens.
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-004867-35 Sponsor Protocol Number: ADA109057 Start Date*: 2016-12-21
    Sponsor Name:GlaxoSmithKline Research and Development Ltd.
    Full Title: A 52-week, Randomized, Double-Blind, Parallel-Group Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 mcg BID and Fluticasone Propionate (FP) DISKUS 250 mcg BID in ...
    Medical condition: Asthma
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-002771-40 Sponsor Protocol Number: PIX-01 Start Date*: 2006-08-28
    Sponsor Name:S.G.O. Johansson, MD PhD Professor
    Full Title: Importance of IgE antibody fraction size on allergen sensitivity of basophils from cat allergic patients on Xolair. A pilot study.
    Medical condition: Allergic asthma and or rhinitis due to allergy to cat dander
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003204-70 Sponsor Protocol Number: DOM-STA-2014-01 Start Date*: 2015-04-24
    Sponsor Name:Dr. Javier Domínguez Ortega
    Full Title: Pilot study on asthma control in patients with grass- pollen allergic rhinitis treated with 5 grass-pollen sublingual immunotherapy (Staloral®) vs placebo
    Medical condition: Respiratory Allergy: Asthma and allergic rhinitis due to grass pollen
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001339-33 Sponsor Protocol Number: SCITVITD3 Start Date*: 2018-07-05
    Sponsor Name:Academisch medisch centrum Amsterdam
    Full Title: A randomized, double-blind, placebo-controlled, study to determine the added value of vitamin D3 to treatment with subcutaneous immunotherapy in patients with moderate to severe allergic rhinitis/ ...
    Medical condition: subcutaneous immunotherapy in allergic rhinitis (AR) patients with allergies to birchpollen
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000279-15 Sponsor Protocol Number: CP009 Start Date*: 2014-07-03
    Sponsor Name:Circassia Limited
    Full Title: A Multi-Centre, Single-Blind Study to Assess the Safety of Cat-PAD in Cat Allergic Paediatric Subjects.
    Medical condition: Treatment of cat-allergen induced rhinoconjunctivitis in paediatric subjects with clinically relevant symptoms
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004855 10034382 Perennial allergic rhinitis LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-001591-11 Sponsor Protocol Number: 3.4.11.049 Start Date*: 2012-12-21
    Sponsor Name:Erasmus MC
    Full Title: Symptomatic treatment of pollen related allergic rhinoconjunctivitis and the relation with asthma with children in the General practice
    Medical condition: Allergic Rhinitis Asthma
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-003572-19 Sponsor Protocol Number: V00114 CP 302 2A Start Date*: 2007-12-04
    Sponsor Name:Pierre Fabre Médicament
    Full Title: EFFICACY AND SAFETY STUDY OF THE ANTIHISTAMINE V0114CP 2.5MG IN THE TREATMENT OF PERENNIAL ALLERGIC RHINITIS. RANDOMISED, DOUBLE-BLIND, THREE ARM PARALLEL GROUP STUDY INCLUDING PLACEBO AND ACTIV...
    Medical condition: The intended indication for the product under development is the treatment of perennial allergic rhinitis.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Prematurely Ended) LT (Prematurely Ended) CZ (Completed) GB (Prematurely Ended) ES (Completed) FI (Prematurely Ended) LV (Completed) AT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 21 08:04:47 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA